Comparative Pharmacology
Head-to-head clinical analysis: TARACTAN versus TRIFLUOPERAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TARACTAN versus TRIFLUOPERAZINE HYDROCHLORIDE.
TARACTAN vs TRIFLUOPERAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Trifluoperazine is a typical antipsychotic of the phenothiazine class. It blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system, reducing dopaminergic neurotransmission. It also has antiemetic effects via dopamine blockade in the chemoreceptor trigger zone and possesses anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
5-10 mg orally twice daily (maximum 40 mg/day), or 1-2 mg intramuscularly every 4-6 hours for acute symptoms (maximum 10 mg/day).
None Documented
None Documented
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life: 12–24 hours; clinical context: requires 5–7 days to reach steady state; may be prolonged in elderly or hepatic impairment
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Primarily renal (approximately 70% as metabolites, <1% unchanged); fecal (approximately 30% via bile)
Category C
Category A/B
Typical Antipsychotic
Typical Antipsychotic